New strategies for preventing epileptogenesis: perspective and overview

Non-clinical toxicity of (+)-limonene epoxide and its physio-pharmacological properties on neurological disorders

The compound (+)-limonene epoxide has antioxidant, anxiolytic, and antihelminthic properties. However, investigations to determine its long-term exposure were not performed. We investigated the systemic toxicological profile after chronic exposure as well as the antidepressant and antiepileptic potentialities of (+)-limonene epoxide on mice. Initially, we evaluated acute toxicity on Artemia salina nauplii and cytotoxicity on mice erythrocytes and peripheral blood mononuclear cells (PBMC). Aftterwards, mice were chronically treated for 120 days by gavage with (+)-limonene epoxide (25, 50, and 75 mg/kg/day) and this exposure was assessed by pathophysiological measurements. For antidepressant and anticonvulsivant analysis, we performed the forced swimming and tail suspension protocols and pentylenetetrazol- and picrotoxin-induced seizures, respectively. (+)-Limonene epoxide showed a LC50 value of 318.7 μg/mL on A. salina shrimps, caused lysis of red blood cells at higher concentrations only but did not show cytotoxicity on PMBC, which suggests pharmacological safety if plasma concentrations do not exceed 100 μg/mL. Macroscopic, hematological, clinical chemistry, and nutritional changes were not detected, though focal areas of hepatic necrosis, inflammatory infiltrate, and karyolysis have been detected at 75 mg/kg/day. The compound inhibited the developing of pentylenetetrazol- and picrotoxin-induced seizures, decreased deaths, and reduced immobility times, mainly at 75 mg/kg. So, it reversed reserpine effects, suggesting antidepressant effects should be linked to serotonergic and/or adrenergic transmission. It is feasible that (+)-limonene epoxide plays a benzodiazepine-like anticonvulsive action and may be also recommended as an antidote for poisonings caused by central depressants.

Functional imaging of seizures and epilepsy: evolution from zones to networks

PURPOSE OF REVIEW

Epilepsy research has extended from studies at the cellular level to the investigation of interactions of large neuronal populations distant from one another: 'epileptic networks'. This article underlines the concept of epilepsies as network disorders, adding empirical evidence from electroencephalography-combined functional MRI (EEG-fMRI) studies.

RECENT FINDINGS

These noninvasive in-vivo EEG-fMRI epilepsy studies have characterized the ictal temporal-spatial evolution and the interictal persistence of altered activity in typical sets of (sub)cortical brain regions responsible for the clinical manifestation of the disease and its underlying encephalopathy, for example, thalamus vs. cortex in generalized; hippocampus vs. cortex in temporal lobe; a frontal near-piriform region universally in focal epilepsies. Models exist validated against intracranial EEG that can explain interictal and ictal activity based on statistical coupling between different brain regions, and if extended could guide the design of new treatments.

SUMMARY

The appreciation of epileptic processes at the network level will foster the development of both anticonvulsive as well as true antiepileptic treatment strategies locally modulating hub regions within the epileptic network architecture as well as entire networks by targeting their characteristic properties such as neurotransmitter or neuronal firing profiles. Treatment should reach beyond seizure control and include the improvement of cognitive function.